The R&D arm of the company is an innovation based model leveraging China and South Africa to foster clinical development – allows for testing in Asian, Caucasian and African subsets.
Access to leading international academic institutions and its researchers and scientists i.e. OXFORD UNIVERSITY.
The company targets China disease areas with a high unmet medical need and affordibility challenge.
Built a team with experience in GLOBAL and CHINA based clinical trials – critical to success is study design and placement of studies in leading Chinese and South African drug development sites.
The model is designed to target category 1 registration processes in China which will include pre-clinical and clinical processes engineered back into China. The company will also ensure API and finished goods are manufactured back into China.
The Nuance model allows to maximize R&D investment by fully capturing the China commerical rights as well as leveraging global royaly agreements should Nuance funded data be used ex China and South Africa.
The company is guided by a leading group of researchers from CHINA and GLOBAL alike – currently a leading oncology advisory board is in place.